/PRNewswire/ J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, at the 8th.
/PRNewswire/ J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI JIN-A02 was presented at the 2023 IASLC.
/PRNewswire/ J INTS BIO announced the successful dosing of the first patient in its global multi-center Phase 1/2 clinical study of JIN-A02 on 31st July.
/PRNewswire/ Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for.